Clinical and histologic features of adults with alpha-1 antitrypsin deficiency in a non-cirrhotic cohort
Author(s): ,
Mark Brantly
Affiliations:
Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, United States
,
Joanna Nolte
Affiliations:
Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, United States
,
Tracie Kurtz
Affiliations:
Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, United States
,
Jonathan Shuster
Affiliations:
Department of Health Outcomes and Policy, University of Florida, United States
,
Amy Collinsworth
Affiliations:
Department of Pathology, Immunology, and Laboratory Medicine, University of Florida, United States
,
Chen Liu
Affiliations:
Department of Pathology and Laboratory Medicine, Rutgers New Jersey Medical School, United States
,
George Marek
Affiliations:
Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, United States
Virginia C. Clark
Affiliations:
Division of Gastroenterology, Hepatology, and Nutrition, University of Florida, United States
Corresponding author. Address: 1600 SW Archer Rd, Box 100277, Rm M440, Gainesville, FL 32610, United States. Tel.: 352-273-9491; fax: 352-392-7393.
EASL LiverTree™. Clark V. Dec 1, 2018; 256745
Virginia Clark
Virginia Clark
Contributions
Journal Abstract
References
Graphical abstract

Graphical abstract

Frequency of unsuspected liver fibrosis in alpha-1 antitrypsin deficiency is high. Alpha-1 antitrypsin within the liver is variable and may explain clinical phenotype. Metabolic syndrome is a risk factor for liver fibrosis.

Background & Aims

Alpha-1 antitrypsin deficiency (AATD) is an uncommonly recognized cause of liver disease in adults, with descriptions of its natural history limited to case series and patient-reported data from disease registries. Liver pathology is limited to selected patients or unavailable. Therefore, we aimed to determine the prevalence and severity of liver fibrosis in an adult AATD population who were not known to have cirrhosis, while defining risk factors for fibrosis and testing non-invasive markers of disease.

Methods

A total of 94 adults with classic genotype ‘PI*ZZ’ AATD were recruited from North America and prospectively enrolled in the study. Liver aminotransferases and markers of synthetic function, transient elastography, and liver biopsy were performed.

Results

The prevalence of clinically significant liver fibrosis (F ≥ 2) was 35.1%. Alanine aminotransferase, aspartate aminotransferase and gamma-glutamyltransferase values were higher in the F ≥ 2 group. Metabolic syndrome was associated with the presence of clinically significant fibrosis (OR 14.2; 95% CI 3.7–55; p <0.001). Additionally, the presence of accumulated abnormal AAT in hepatocytes, portal inflammation, and hepatocellular degeneration were associated with clinically significant fibrosis. The accuracy of transient elastography to detect F ≥ 2 fibrosis was fair, with an AUC of 0.70 (95% CI 0.58–0.82).

Conclusions

Over one-third of asymptomatic and lung affected adults with ‘PI*ZZ’ AATD have significant underlying liver fibrosis. Liver biopsies demonstrated variable amounts of accumulated Z AAT. The risk of liver fibrosis increases in the presence of metabolic syndrome, accumulation of AAT in hepatocytes, and portal inflammation on baseline biopsy. The results support the hypothesis that liver disease in this genetic condition may be related to a “toxic gain of function” from accumulation of AAT in hepatocytes.

Lay summary

Individuals diagnosed with classic alpha-1 antitrypsin deficiency (ZZ) are at risk of liver injury and scarring, because of the accumulation of abnormal alpha-1 antitrypsin in the liver. A liver biopsy in ZZ individuals can demonstrate the accumulation of alpha-1 antitrypsin within the liver and identify if any associated liver scarring is present. Indviduals with large amounts of alpha-1 antitrypsin on biopsy may be at risk of liver injury and fibrosis. Additional common medical conditions of diabetes, obesity, high cholesterol, and hypertension (known as metabolic syndrome) are associated with a greater degree of liver injury.

Clinical Trial number

clinicaltrials.gov NCT01810458.

Keyword(s)
Liver cirrhosis, Hepatocytes, Alpha-1 antitrypsin deficiency, Prevalence, Risk factors, Metabolic syndrome, Elasticity imaging techniques
[1]. M. Brantly - Molecular basis of alpha-1-antitrypsin deficiency
[2]. D.A. Lomas - The mechanism of Z alpha 1-antitrypsin accumulation in the liver
[3]. C.M. Greene - Alpha1-antitrypsin deficiency
[4]. D. Lindblad - Alpha-1-antitrypsin mutant Z protein content in individual hepatocytes correlates with cell death in a mouse model
[5]. S. Guo - Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin-related liver disease in mice
[6]. T. Hidvegi - An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis
[8]. S.A. Townsend - Systematic review: the natural history of alpha-1 antitrypsin deficiency, and associated liver disease
[9]. J.K. Stoller - Mortality in individuals with severe deficiency of alpha1-antitrypsin: findings from the National Heart, Lung, and Blood Institute Registry
[10]. C. Larsson - Natural history and life expectancy in severe alpha1-antitrypsin deficiency, Pi Z.
[11]. H.A. Tanash - Clinical course and prognosis of never-smokers with severe alpha-1-antitrypsin deficiency (PiZZ)
[12]. H.A. Tanash - Survival in severe alpha-1-antitrypsin deficiency (PiZZ)
[13]. T. Sveger - Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants
[14]. E. Bernspang - The liver in 30-year-old individuals with alpha(1)-antitrypsin deficiency
[15]. H.A. Tanash - The Swedish alpha1-antitrypsin screening study: health status and lung and liver function at age 34
[16]. B. Mostafavi - Liver function in alpha-1-antitrypsin deficient individuals at 37 to 40 years of age
[17]. D.W. Cox - Risk for liver disease in adults with alpha 1-antitrypsin deficiency
[18]. S. Eriksson - Alpha 1-antitrypsin deficiency and liver cirrhosis in adults. An analysis of 35 Swedish autopsied cases
[19]. A.N. Elzouki - Risk of hepatobiliary disease in adults with severe alpha 1-antitrypsin deficiency (PiZZ): is chronic viral hepatitis B or C an additional risk factor for cirrhosis and hepatocellular carcinoma?
[20]. V.C. Clark - Liver test results do not identify liver disease in adults with alpha(1)-antitrypsin deficiency
[21]. C.L. Bowlus - Factors associated with advanced liver disease in adults with alpha1-antitrypsin deficiency
[22]. M.F. Dawwas - Prevalence and risk factors for liver involvement in individuals with PiZZ-related lung disease
[23]. D.F. Reinert - The alcohol use disorders identification test: an update of research findings
[24]. K.G. Alberti - Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity
[25]. P. Bedossa - Histological assessment of NAFLD
[26]. L. Castera - Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations
[27]. L. Morer - Liver involvement in patients With PiZZ-emphysema, candidates for lung transplantation
[28]. C. Strange - Results of a survey of patients with alpha-1 antitrypsin deficiency
[29]. C. Trautwein - Hepatic fibrosis: concept to treatment
[30]. G. Vernon - Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults
[31]. J. Ludwig - The liver biopsy diagnosis of Wilson’s disease. Methods in pathology
[32]. H. Nakagawa - ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development
[33]. U. Ozcan - Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes
[34]. A. Ordonez - Endoplasmic reticulum polymers impair luminal protein mobility and sensitize to cellular stress in alpha1-antitrypsin deficiency
[35]. D.T. Rutkowski - UPR pathways combine to prevent hepatic steatosis caused by ER stress-mediated suppression of transcriptional master regulators
[36]. G.S. Hotamisligil - Endoplasmic reticulum stress and the inflammatory basis of metabolic disease
[37]. J.H. Teckman - Baseline analysis of a young alpha-1-antitrypsin deficiency liver disease cohort reveals frequent portal hypertension

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies